The NSW Hepatitis C Remote Prescribing Program was established in November 2020 to facilitate linkages between nurses and prescribers to increase access to treatment in regional areas. Funded by NSW Health and coordinated by ASHM, the program has since been extended to other settings where treatment may otherwise be limited, including Mental Health services, Alcohol and Other Drugs services, Aboriginal Medical Services, and homelessness settings.
The program utilises a nurse-led and patient-centred model of care. Nurses perform the initial hepatitis C assessment and patient work-up then refer to prescribers who review the information and initiate direct acting antiviral (DAA) therapy. Several resources have been developed and/or tailored to facilitate the efficient exchange of clinical information and virtual prescribing. Only patients who meet the Remote Consultation Criteria, i.e., patients must be non-cirrhotic or have compensated cirrhosis and have no significant co-morbidities, can be included in the program.
Over the past 3 years, the NSW Hepatitis C Remote Prescribing Program’s model of care has demonstrated highly successful outcomes, enabling over 210 patients to be initiated onto treatment. Whilst all medical practitioners and authorised nurse practitioners can prescribe direct acting antiviral (DAA) therapy for the treatment of hepatitis C, the program can expedite and facilitate increased access to treatment in patients’ preferred settings. Nurses participating in the program provide flexible, patient-centred, on-treatment support, harm minimisation education and individualised follow-up to help these patients through treatment and achieve hepatitis C cure.
Interested NSW-based practitioners and nurses are invited to join the program as prescribers and referrers respectively by emailing NSWLinkages@ashm.org.au.
For more information about hepatitis C, see the ASHM resources page and the Reach-C website at which provides an online form for practitioners who are not already experienced in hepatitis C treatment to gain specialist approval within 24 hrs to initiate DAA therapy.
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: Are your vaccines ready for summer? In the summer season, storms are more likely to occur, which can lead to power outages. Refer to the Cold Chain Toolkit to ensure all vaccination storage requirements are in place should an outage occur. Disposal of Zostavax® Zostavax® vaccine will…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
NSW urged to prepare for heat wave Severe heatwave conditions are forecast in NSW in the coming days. Please read the NSW Health media release about taking steps to prevent heat-related illness. For further information about staying safe in a heatwave, visit Beat the heat and stay well during hot…